Evofem Biosciences

200 articles about Evofem Biosciences

• Evofem Biosciences to Report Fourth Quarter and Year-end 2019 Results and Provide Corporate Update on March 12, 2020

  3/3/2020

  Evofem Biosciences, Inc. will hold a webcast and conference call to discuss the Company's financial results and business highlights for the fourth quarter and year ended December 31, 2019..

• 

  BioSpace Movers & Shakers, Feb. 28

  2/28/2020

  Biopharma and life sciences strengthen their executive leadership teams and boards with this week's Movers & Shakers.

• Evofem Biosciences Appoints Former FDA Division Director Lisa Rarick, M.D., to its Board of Directors

  2/26/2020

  - Distinguished Career at the U.S. Food and Drug Administration in CDER and the Office of Women's Health; Significant Industry and Regulatory Expertise -

• 

  The Next Big Thing in Birth Control: Amphora Offers Women a Missing Option

  1/22/2020

  Amphora is a viscous and bioadhesive contraceptive, packaged in a prefilled applicator.

• U.S. FDA Acknowledges Receipt of Evofem Biosciences' New Drug Application Resubmission for Amphora® for the Prevention of Pregnancy

  12/18/2019

  Evofem Biosciences, Inc., a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration acknowledged receipt of the New Drug Application resubmission for Amphora®, a Multipurpose Vaginal pH Regulator, for the prevention of pregnancy.

• PDL BioPharma Congratulates Evofem Biosciences on Achieving Major Regulatory and Clinical Milestones with its Lead Product Candidate Amphora®

  12/3/2019

  The first milestone was the resubmission of the Amphora New Drug Application to the U.S. Food and Drug Administration for the prevention of pregnancy that was announced November 26, 2019. 

• Evofem Biosciences Reports Positive Top-Line Results from Phase 2b Study of Amphora® for Prevention of Chlamydia and Gonorrhea in Women

  12/2/2019

  Evofem Biosciences, Inc. (NASDAQ: EVFM), a clinical stage biopharmaceutical company, today announced positive top-line results from AMPREVENCE, a Phase 2b clinical trial evaluating the efficacy and safety of its lead product candidate Amphora® for the prevention of urogenital chlamydia and gonorrhea in women.

• 

  Up-and-Coming Female Powerhouses of Biotech

  11/19/2019

  Balancing slim chances with a drive for success, each of these women beat the biotech odds.

• Evofem Biosciences' CEO Saundra Pelletier Awarded 2019 Business Woman Of The Year

  11/14/2019

  Evofem Biosciences, Inc. (NASDAQ: EVFM) today announced that Chief Executive Officer Saundra Pelletier was named a 2019 Business Woman of the Year by the San Diego Business Journal.

• Evofem Biosciences to Participate in Upcoming Investor Conferences - Nov. 13, 2019

  11/13/2019

  Evofem Biosciences, Inc., a clinical-stage biopharmaceutical company, announced that Chief Executive Officer Saundra Pelletier will present at two upcoming healthcare equity conferences

• Evofem Biosciences Reports Third Quarter 2019 Financial Results and Provides Corporate Update

  11/6/2019

  Evofem Biosciences, Inc. a clinical-stage biopharmaceutical company, reported financial results for the three- and nine-month periods ended September 30, 2019.

• Evofem Biosciences to Report Third Quarter 2019 Results and Provide Corporate Update on November 7, 2019

  10/24/2019

  Conference Call Scheduled for 11:00 a.m. EST

• Evofem Biosciences to Present at Cantor Global Healthcare Conference on October 4, 2019

  9/25/2019

  Evofem Biosciences, Inc., (NASDAQ: EVFM), a clinical-stage biopharmaceutical company, will present and host investor meetings at the upcoming 2019 Cantor Global Healthcare Conference in New York, NY.

• Evofem Biosciences Completes Phase 2b 'AMPREVENCE' Trial of Amphora for Prevention of Chlamydia and Gonorrhea in Women

  8/26/2019

  Evofem Biosciences, Inc. announced the last patient has completed her last visit in AMPREVENCE, the Phase 2b clinical trial evaluating the Company's lead product candidate Amphora®, a Multipurpose Vaginal pH Regulator, for the prevention of acquisition of chlamydia and gonorrhea in women.

• Evofem Biosciences to Present at Upcoming Healthcare Conferences

  8/22/2019

  Set to present at two healthcare equity conferences in early September.

• Evofem Biosciences Reports Second Quarter 2019 Financial Results and Provides Corporate Update

  8/5/2019

  Amphora NDA Resubmission Remains on Track for Q4 2019 Management to Host Conference Call Tuesday August 6, 2019 at 11:00 a.m. EDT

• Evofem Biosciences Reports Additional Data from Phase 3 'AMPOWER' Study of Amphora® for Hormone-Free Birth Control

  8/5/2019

  Evofem Biosciences, Inc., a clinical-stage biopharmaceutical company, reported additional data from its Phase 3 'AMPOWER' clinical trial of Amphora® for the prevention of pregnancy.

• Evofem Biosciences to Report Second Quarter 2019 Results and Provide Corporate Update on August 6, 2019

  7/30/2019

  Conference Call Scheduled for 11:00 a.m. EDT

• Evofem Biosciences Added to Russell 3000® Index

  7/1/2019

  Effective at the U.S. market open on July 1, 2019, according to a final list of additions posted June 28.

• Evofem Biosciences Closes $80 Million Financing Transaction with PDL BioPharma and Other Long-time Investors

  6/10/2019

   Evofem Biosciences, Inc. (NASDAQ: EVFM) (Evofem), a clinical-stage biopharmaceutical company, and PDL BioPharma, Inc. (Nasdaq: PDLI) (PDL) today announced the closing of the second tranche for $50 million of an aggregate $80 million strategic financing from PDL and existing Evofem investors, Invesco Asset Management, LTD. (Invesco) and Woodford Investment Management (WIM).